Sodium Butyrate: A Literature Course in Six Modules

About this course

This course walks through the published sodium butyrate literature in six modules, summarising what individual papers investigated, in what model, and what the authors reported. It is organised so that mechanism, outcomes, adverse-event reporting, pharmacokinetics and regulatory status are kept separate, because these areas are supported by very different amounts of evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no dose is stated unless the cited paper's own reporting supports it.

One framing note: sodium butyrate is not a peptide. It appears in peptide-adjacent research reading lists because it is studied alongside metabolic, gut-barrier and immunomodulatory interventions, and because its mechanisms — histone modification, receptor signalling, macrophage phenotype — overlap with topics that recur in that literature.

Module 1: What Sodium Butyrate Is and How It Has Been Studied

Definition and class. Sodium butyrate is the sodium salt of butyric acid, a four-carbon short-chain fatty acid (SCFA). Chemically it belongs to the SCFA salts, not to peptides, hormones or growth factors. In biology it is best known as a fermentation end-product: colonic bacteria generate butyrate from dietary fibre, and the compound then acts on intestinal epithelium and immune cells locally before any systemic distribution.

Origin as described in studies. The microbial origin is explicit in the study titles themselves. A 2022 report in Molecular Immunology described "gut microbial sodium butyrate" and reported that it alleviated renal ischemia–reperfusion injury through HES1/PPARα regulation (PMID 35930845). That framing — an endogenous microbial metabolite that is also administered exogenously as a salt — explains why the literature spans microbiome science, gastroenterology, oncology and immunology.

Forms and routes used in published work

• Oral supplementation in rodents. A 2022 study in Biomedicine & Pharmacotherapy used oral sodium butyrate supplementation and reported amelioration of paclitaxel-induced behavioral and intestinal dysfunction (PMID 36076609).
• In vitro exposure of cultured cells. A 2025 report in Molecular Medicine was explicitly labelled "in vitro" and reported that sodium butyrate regulated macrophage polarization via TGR5/β-arrestin2 (PMID 39881219).
• Microbiological assay systems. A 2019 Microbial Pathogenesis paper reported inhibition of planktonic cells and biofilms of Trichosporon spp. (PMID 30878621).

Limits of the evidence in Module 1

The verified papers in this course are cell-culture and animal studies. None of them is a randomised controlled trial in humans, and none establishes that sodium butyrate behaves in people the way it behaves in a culture dish or a rodent model. Definitions and forms described above are descriptive chemistry and study design, not evidence of clinical usefulness.

Module 2: Mechanism as Described in the Literature

Mechanistic papers on sodium butyrate cluster into four broad themes. Each theme below reflects what the cited authors reported in their own model system.

Epigenetic and histone-modifying activity

The most frequently invoked mechanism is inhibition of histone deacetylases. A 2024 study in Inflammation reported that sodium butyrate ameliorated atopic dermatitis-induced inflammation by inhibiting HDAC3-mediated STAT1 and NF-κB signalling (PMID 38159175). A second, distinct epigenetic route was described in 2025 in Molecular and Cellular Biochemistry, where researchers reported that sodium butyrate attenuated liver fibrogenesis via promotion of H4K8 crotonylation (PMID 40180786) — a histone acylation mark rather than acetylation.

Receptor-mediated and immune-cell signalling

Beyond chromatin, the literature describes surface-receptor signalling. The 2025 Molecular Medicine in vitro work reported that macrophage polarization shifted through a TGR5/β-arrestin2 axis (PMID 39881219). A 2025 paper in BBA – Molecular Basis of Disease reported that sodium butyrate alleviated colitis by inhibiting mitochondrial ROS-mediated macrophage pyroptosis (PMID 40044062), and a 2026 Nutrients report described modulation of SIRT1-involved ferroptosis together with inhibition of macrophage ferroptosis in inflammatory bowel disease models (PMID 41754114). Macrophages recur across these papers as the cell type whose death pathway or phenotype was reported to change.

Metabolic reprogramming

In cancer models, metabolism is the reported target. A 2024 study in Chemico-Biological Interactions reported that sodium butyrate blocked colorectal cancer growth by inhibiting aerobic glycolysis mediated by SIRT4/HIF-1α (PMID 39241941). A 2019 paper in the Journal of Physiology and Biochemistry reported induction of autophagy in colorectal cancer cells through LKB1/AMPK signalling (PMID 30362049), linking the compound to an energy-sensing kinase cascade.

Regulated cell death — direction depends on the cell

Ferroptosis, an iron-dependent form of cell death, appears on both sides of the ledger. In tumour cells the reported effect was induction: a 2023 Apoptosis study reported ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis (PMID 37170022), and a 2025 International Immunopharmacology study reported ferroptosis in colorectal cancer cells through NCOA4–FTH1-mediated ferritinophagy (PMID 40652583). In intestinal inflammation models, by contrast, the 2026 Nutrients report described inhibition of macrophage ferroptosis (PMID 41754114).

Limits of the evidence in Module 2

These mechanisms were identified in separate models with different readouts; they have not been reconciled into a single validated pathway map. Pathway inhibition or induction in one cell type does not predict the same event in another, as the opposite-direction ferroptosis findings illustrate. Mechanistic plausibility is also not evidence of clinical effect — none of these papers measured patient-level outcomes.

Module 3: Reported Outcomes by Study

The table below groups the verified reports by model and by what researchers measured. Each row states the reported result only as the authors framed it; no row implies a benefit in humans.

Limits of the evidence in Module 3

Every row is a preclinical result. Disease-model endpoints such as "colitis alleviated" describe scores, histology or molecular markers within that experiment, not symptom relief in people. Positive findings in cell lines and induced animal models historically translate to human benefit only a minority of the time, and none of these studies was designed to test translation. Effect sizes, comparator arms and blinding varied by paper and are not summarised here.

Module 4: Sodium Butyrate Side Effects: What Studies Report

This module is deliberately short, because the verified literature is thin on adverse-event reporting — and that absence is itself the finding.

None of the cited papers was a safety or toxicology study. The 2022 rodent work that used oral sodium butyrate supplementation framed its endpoints around paclitaxel-induced behavioral and intestinal dysfunction rather than around tolerability surveillance (PMID 36076609). Similarly, the 2025 colitis study reported disease-model and mechanistic endpoints centred on macrophage pyroptosis (PMID 40044062), and the 2025 liver fibrosis study reported fibrogenesis and histone crotonylation endpoints (PMID 40180786). No adverse-event tables, dropout rates or dose-limiting toxicities are described in the scope of these reports.

Cell-death induction is a mechanistic caveat worth reading carefully. Several papers reported that sodium butyrate induced regulated cell death in tumour cells — ferroptosis via RBM3/SLC7A11 in endometrial cancer cells (PMID 37170022), ferroptosis via NCOA4–FTH1 ferritinophagy in colorectal cancer cells (PMID 40652583), and autophagy via LKB1/AMPK in colorectal cancer cells (PMID 30362049). Those observations were made in cancer cell lines and were reported as anti-tumour mechanisms, not as harms; they nonetheless show that the compound engages cell-death machinery, which is a reason researchers treat selectivity as an open question rather than a settled one.

Limits of the evidence in Module 4

Absence of reported adverse events in mechanistic papers is not evidence of safety. Without human dose-ranging, no statement can be made about tolerability, interaction risk, or effects in any specific population. Readers looking for a documented side-effect profile will not find one in this body of work.

Module 5: Pharmacokinetics Where Data Exist

The verified papers in this course did not report human pharmacokinetic parameters — no absorption fraction, half-life, volume of distribution, clearance or bioavailability figures fall within their scope. What the literature does supply is route and exposure context.

• Oral route feasibility in animals. The 2022 rodent study administered sodium butyrate as oral supplementation and reported effects on behavioral and intestinal endpoints (PMID 36076609), indicating that an oral route was used successfully in that model without establishing systemic exposure values.
• Endogenous production as the baseline. The 2022 renal study described butyrate as a gut microbial product and reported HES1/PPARα-mediated effects on ischemia–reperfusion injury (PMID 35930845), a reminder that colonic fermentation continuously produces the same molecule.
• Direct-exposure systems. In vitro macrophage work applied the compound directly to cells and reported TGR5/β-arrestin2-dependent polarization changes (PMID 39881219), so culture concentrations in such designs do not correspond to any achievable plasma level.

Limits of the evidence in Module 5

Because pharmacokinetic data are absent from these reports, no bridge exists between concentrations used in vitro, doses used in animals, and anything measurable in humans. Short-chain fatty acids are also extensively metabolised by colonocytes and the liver, which is a general pharmacological consideration rather than a finding from any cited paper here. Any numeric dose conversion would be speculation and is therefore omitted.

Module 6: Regulatory Status

Regulatory facts below are stated descriptively and are not a comment on any product.

• Not an approved drug for the indications studied. Sodium butyrate is not an FDA-approved prescription drug product for colitis, inflammatory bowel disease, liver fibrosis, kidney injury, atopic dermatitis or any cancer. The studies summarised in Module 3 are preclinical investigations, not registration trials.
• Research-use-only material. Sodium butyrate supplied for laboratory work is commonly labelled research use only (RUO). RUO material is intended for in vitro or laboratory investigation and is not manufactured, tested or labelled for human administration.
• Food, supplement and animal-nutrition contexts. Butyrate salts appear in some jurisdictions as dietary ingredients or as animal feed additives. Those categories are regulated differently from drugs: they do not involve pre-market efficacy review, and category placement varies by country.
• Compounding. In the United States, pharmacies compounding under sections 503A and 503B may use bulk drug substances only when those substances meet defined statutory and FDA-list criteria. Lists and agency positions change over time, so status should be verified against current FDA and state board sources rather than assumed.

This section is general regulatory information, not legal advice.

Limits of the evidence in Module 6

Regulatory classification says nothing about biological activity, and biological activity in the papers above says nothing about regulatory approval. A molecule can be an endogenous metabolite, a feed additive and an unapproved drug candidate simultaneously.

What the Studies Did Not Test

Reading the verified set as a whole, the gaps are as important as the findings:

1. Humans. No cited paper reported a human clinical trial; endpoints came from cell lines and animal disease models such as colitis (PMID 40044062) and renal ischemia–reperfusion (PMID 35930845).
2. Long-term exposure. The oral supplementation study addressed chemotherapy-associated dysfunction endpoints rather than chronic multi-year dosing (PMID 36076609).
3. Healthy-tissue selectivity. Ferroptosis was reported as induced in cancer cells (PMID 40652583) and as inhibited in macrophages in an IBD model (PMID 41754114), and no cited study resolved how that opposite direction is determined across tissues.
4. Combination and interaction effects. Apart from the chemotherapy-model context, drug–drug and drug–microbiome interactions were not endpoints in these reports.
5. Clinical antimicrobial use. The Trichosporon work reported inhibition of planktonic cells and biofilms in laboratory assays (PMID 30878621), not treatment of infection in a patient.

The reasonable summary is that sodium butyrate has a large, internally varied preclinical literature describing epigenetic, receptor-level and metabolic mechanisms, and that the clinical evidence base needed to translate any of it remains undone in the papers cited here.

References

• Sodium Butyrate Ameliorates Atopic Dermatitis-Induced Inflammation by Inhibiting HDAC3-Mediated STAT1 and NF-κB Pathway (Inflammation, 2024)
• Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis (Apoptosis, 2023)
• Sodium butyrate blocks the growth of colorectal cancer by inhibiting the aerobic glycolysis mediated by SIRT4/HIF-1α (Chemico-Biological Interactions, 2024)
• Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro (Molecular Medicine, 2025)
• Sodium butyrate alleviates colitis by inhibiting mitochondrial ROS mediated macrophage pyroptosis (BBA – Molecular Basis of Disease, 2025)
• Sodium butyrate attenuates liver fibrogenesis via promoting H4K8 crotonylation (Molecular and Cellular Biochemistry, 2025)
• Sodium Butyrate Alleviates IBD by Modulating SIRT1-Involved Ferroptosis and Inhibition of Macrophage Ferroptosis (Nutrients, 2026)
• Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction (Biomedicine & Pharmacotherapy, 2022)
• Sodium butyrate inhibits planktonic cells and biofilms of Trichosporon spp (Microbial Pathogenesis, 2019)
• Gut microbial sodium butyrate alleviates renal ischemia-reperfusion injury by regulating HES1/PPARα (Molecular Immunology, 2022)
• Sodium butyrate induces autophagy in colorectal cancer cells through LKB1/AMPK signaling (Journal of Physiology and Biochemistry, 2019)
• Sodium butyrate induces ferroptosis in colorectal cancer cells by promoting NCOA4-FTH1-mediated ferritinophagy (International Immunopharmacology, 2025)